SPRINT Subanalysis: Intensive SBP Control in Prediabetes vs Normal Fasting Blood Glucose
The primary outcome of the analysis was a composite of nonfatal acute coronary syndrome, stroke, heart failure, or cardiovascular disease death.
This article is part of Endocrinology Advisor's coverage of the American Diabetes Association's 77th Scientific Sessions (ADA 2017), taking place in San Diego, CA. Our staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back regularly for more news from ADA 2017.
Intensive systolic blood pressure (SBP) treatment outcomes were similar between groups of patients with prediabetes and with normal fasting blood glucose levels, according to research presented at the American Diabetes Association (ADA) 77th Scientific Sessions, held June 9-13 in San Diego, California.
Researchers performed a subgroup analysis of participants from SPRINT (Systolic Blood Pressure Intervention Trial; ClinicalTrials.gov identifier: NCT01206062) to examine the effect of intensive vs standard SBP therapy on either the primary outcome or all-cause mortality among participants with prediabetes vs participants with normal fasting blood glucose levels.
Within the subgroup analysis, 3898 patients had prediabetes (fasting blood glucose ≥100 mg/dL) and 5425 patients had normal fasting blood glucose levels (<100 mg/dL). During a median 3.3 years follow-up, the hazard ratio (HR) for the primary outcome (a composite of nonfatal acute coronary syndrome, stroke, heart failure, or cardiovascular disease death) was 0.83 (95% CI, 0.66-1.03) vs 0.69 (95% CI, 0.53-0.89; P interaction =.30) for participants with normal fasting blood glucose levels and prediabetes, respectively; HRs for all-cause mortality were 0.71 (95% CI, 0.54-0.94) and 0.77 (95% CI, 0.55-1.06; P interaction =.74), respectively.
“In SPRINT, the beneficial effects of SBP control were similar among those with baseline [fasting blood glucose] <100 and ≥100 mg/dL,” the researchers concluded.
Disclosures: Dr Bress reports receiving research support for Novartis AG and the National Institutes of Health. Dr Cheung reports serving as a consultant for Boehringer Ingelheim Pharmaceuticals and reports serving as the DSMB Chair for Baxer clinical trial and as a contributor to Up-to-Date. Dr Evans reports receiving research support from AstraZeneca. Dr Cushman reports serving as an uncompensated consultant for Takeda, as well as receiving research support from Eli Lilly and Company.
Visit Endocrinology Advisor's conference section for continuous coverage from ADA 2017
Bress A, Beddhu S, King J, et al. Intensive blood pressure control reduces cardiovascular events in patients with prediabetes. Presented at: American Diabetes Association 77th Scientific Sessions; June 9-13, 2017; San Diego, CA. Abstract 212-LB.